ADMA Biologics is expected to report Q3 2026 consensus revenue of $139.8 million (+4.16% YoY) and EPS of $0.19 (+18.75% YoY), with its stock currently trading at $11.41 compared to an average analyst target of $18.67.
The key story for this quarter is the continued sales trajectory of Asceniv, which has been offsetting significant declines in the lower-margin Bivigam product line.
Investors are specifically watching for gross margin performance, which reached record levels near 70% last quarter, and management's ability to maintain its reiterated full-year 2026 revenue guidance of $530 million to $560 million.
The report also arrives amid ongoing legal overhangs from securities litigation that has impacted investor sentiment since early 2026.